A Phase 2 interventional study of Valbenazine and Placebo oral capsule in Tourette Syndrome, sponsored by Neurocrine Biosciences. Completed at 35 sites in 2 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-28.
Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.
Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 19th largest by enrollment of the 105 interventional ones that give a count, is one of 5 that started in 2017, is one of 26 in phase 2, and was the 81st registered.
240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.
Browse Tourette Syndrome studies →20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 12–17
University of Minnesota · Sites in United States
Ages 12–21
University of Utah · Sites in United States
Ages 8–17
Vanderbilt University Medical Center · Sites in United States
Ages 11–17 · Healthy volunteers
Boston Children's Hospital · Sites in United States
Ages 0–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 30 · Phase 3 12 · Phase 4 8
First in 1988; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 127 is above the median of 36 across 183 interventional studies indexed under Tourette Syndrome.
Median enrollment 33 across the 105 interventional studies, 90 across the 33 observational. Of the 106 that completed or were terminated, 45 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 139 have an industry lead sponsor. The 10 most frequent:
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
Neurocrine Biosciences has 8 studies filed under Tourette Syndrome — fewer than ten, so there is no comparison to draw.
6 of the studies in Tourette Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05558566Yale UniversityNeurofeedback From the Supplementary Motor Area for Tourette Syndrome | 2026-12-20 |
| NCT01075672Massachusetts General HospitalOutcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals | 2027-01 |
| NCT03914664Vanderbilt University Medical CenterNeural Correlates of Sensory Phenomena in Tourette Syndrome | 2027-02-28 |
| NCT04851678Vanderbilt University Medical CenterLongitudinal Impact of Stressors in Adults With Tourette Syndrome | 2027-03-01 |
| NCT05126888Neurothera Labs Inc.SCI-110 in the Treatment of Tourette Syndrome | 2027-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 139 studies in Tourette Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2b, randomized, double-blind, placebo-controlled, dose-optimization study to evaluate the efficacy, safety, and tolerability of NBI-98854 titrated to the subject's optimal dose administered once daily (qd) for a total of 12 weeks of treatment in pediatric subjects with TS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo (matching valbenazine) once daily for 12 weeks.
Drug: Placebo oral capsule
Participants received valbenazine once daily for 12 weeks. The starting dose was 20 mg for participants \<50 kg at baseline and 40 mg for participants ≥50 kg at baseline, and could be escalated in increments of 20 mg every 2 weeks to a maximum of 60 mg for subjects \<50 kg and 80 mg for subjects ≥50 kg to achieve an optimal dose of valbenazine for each participant.
Drug: Valbenazine
vesicular monoamine transporter 2 (VMAT2) inhibitor
Also known as: Ingrezza, NBI-98854
non-active dosage form
Change From Baseline to Week 12 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)
The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity.
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in the Clinical Global Impression of Tics Severity (CGI-Tics-Severity) Score
The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.
Time frame: Baseline, Week 12
Participants Who Are a Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) Responder at Week 12
A TTS responder is defined, on a per-visit basis, as a participant whose TTS value is reduced by at least 30% from baseline at the specified postbaseline visit.
Time frame: Baseline, Week 12
Participants Who Are a Clinical Global Impression of Tourette Syndrome Improvement (CGI-TS-Improvement) Responder at Week 12
The CGI-TS-Improvement scale is used to assess overall improvement since the initiation of study drug dosing on a 7-point scale. A CGI-TS-Improvement responder is defined, on a per-visit basis, as a participant whose CGI-TS-Improvement score is 1 ("Very much improved") or 2 ("Much improved") at the specified postbaseline visit.
Time frame: Week 12
This study enrolled male and female pediatric participants, 6 to 17 years of age, with a Diagnostic and Statistical Manual of Mental Disorders, 4th or 5th Editions (DSM-IV or -V) diagnosis of Tourette Syndrome (TS) in the United States. The first and last participants were enrolled on 05 October 2017 and 19 July 2018, respectively.
| Milestone | Placebo | Valbenazine |
|---|---|---|
| Started | 64 | 63 |
| Safety analysis set | 62 | 59 |
| Full analysis set | 61 | 58 |
| Completed | 55 | 43 |
| Not completed | 9 | 20 |
| Withdrew: Adverse event | 3 | 8 |
| Withdrew: Protocol violation | 1 | 8 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Lack of efficacy | 2 | 0 |
The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity.
| score on a scale | Placebo | Valbenazine |
|---|---|---|
| Change From Baseline to Week 12 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) | -6.8 ± 1.0 | -8.9 ± 1.1 |
The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.
| Score on scale | Placebo | Valbenazine |
|---|---|---|
| Change From Baseline to Week 12 in the Clinical Global Impression of Tics Severity (CGI-Tics-Severity) Score | -0.7 ± 0.1 | -1.0 ± 0.1 |
A TTS responder is defined, on a per-visit basis, as a participant whose TTS value is reduced by at least 30% from baseline at the specified postbaseline visit.
| Participants | Placebo | Valbenazine |
|---|---|---|
| Participants Who Are a Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) Responder at Week 12 | 21 | 18 |
The CGI-TS-Improvement scale is used to assess overall improvement since the initiation of study drug dosing on a 7-point scale. A CGI-TS-Improvement responder is defined, on a per-visit basis, as a participant whose CGI-TS-Improvement score is 1 ("Very much improved") or 2 ("Much improved") at the specified postbaseline visit.
| Participants | Placebo | Valbenazine |
|---|---|---|
| Participants Who Are a Clinical Global Impression of Tourette Syndrome Improvement (CGI-TS-Improvement) Responder at Week 12 | 12 | 24 |
Collected over Up to 14 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/62 (0%) | 1/62 (1.6%) | 17/62 (27.4%) |
| Valbenazine | 0/59 (0%) | 0/59 (0%) | 32/59 (54.2%) |
| Event | Placebo | Valbenazine |
|---|---|---|
| RashSkin and subcutaneous tissue disorders | 1/62 | 0/59 |
| Event | Placebo | Valbenazine |
|---|---|---|
| HeadacheNervous system disorders | 5/62 | 11/59 |
| SomnolenceNervous system disorders | 0/62 | 11/59 |
| VomitingGastrointestinal disorders | 4/62 | 6/59 |
| FatigueGeneral disorders | 5/62 | 6/59 |
| Suicidal ideationPsychiatric disorders | 1/62 | 5/59 |
| Abdominal pain upperGastrointestinal disorders | 2/62 | 3/59 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/62 | 3/59 |
| NauseaGastrointestinal disorders | 2/62 | 3/59 |
| IrritabilityGeneral disorders | 2/62 | 3/59 |
| InfluenzaInfections and infestations | 1/62 | 3/59 |
Full analysis set, which includes all randomized participants who have at least one evaluable change from baseline value for Total Tic Score reported at a visit (either scheduled or mapped early termination visit) during the treatment period.
| Age, Continuous(Years) | Placebo | Valbenazine | Total |
|---|---|---|---|
| Mean | 12.4 ± 2.6 | 12.2 ± 2.7 | 12.3 ± 2.6 |
| Sex: Female, Male(Participants) | Placebo | Valbenazine | Total |
|---|---|---|---|
| Female | 9 | 10 | 19 |
| Male | 52 | 48 | 100 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Valbenazine | Total |
|---|---|---|---|
| Hispanic or Latino | 15 | 14 | 29 |
| Not Hispanic or Latino | 46 | 44 | 90 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Valbenazine | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 |
| Race — Asian | 3 | 1 | 4 |
| Race — Black or African American | 8 | 1 | 9 |
| Race — White | 49 | 53 | 102 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Race — Other | 0 | 1 | 1 |
| Race — Multiple | 0 | 2 | 2 |
| Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)(score on scale) | Placebo | Valbenazine | Total |
|---|---|---|---|
| Mean | 31.2 ± 9.0 | 29.3 ± 8.7 | 30.3 ± 8.9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Nov 2018, 12 months.
Results were first posted in Jun 2021, 2 years 7 months after primary completion. A results delay was requested in Mar 2019.
Of 19 phase 2 interventional studies under Tourette Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valbenazine